| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5472969 | ACTELION | Method of inhibiting glycolipid synthesis |
May, 2013
(10 years ago) | |
| US5525616 | ACTELION | Method of inhibiting glycolipid synthesis |
Jun, 2013
(10 years ago) | |
Zavesca is owned by Actelion.
Zavesca contains Miglustat.
Zavesca has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zavesca are:
- US5472969
- US5525616
Zavesca was authorised for market use on 31 July, 2003.
Zavesca is available in capsule;oral dosage forms.
The generics of Zavesca are possible to be released after 11 June, 2013.
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 31 July, 2003
Treatment: NA
Dosage: CAPSULE;ORAL
More Information on Dosage
ZAVESCA family patents
